Zobrazeno 1 - 10 of 47 pro vyhledávání: '"Jonathan D. Roth"'
1
Akademický článek
FXR activation by obeticholic acid or nonsteroidal agonists induces a human-like lipoprotein cholesterol change in mice with humanized chimeric liver
Autor: Romeo Papazyan, Xueqing Liu, Jingwen Liu, Bin Dong, Emily M. Plummer, Ronald D. Lewis, II, Jonathan D. Roth, Mark A. Young
Publikováno v: Journal of Lipid Research, Vol 59, Iss 6, Pp 982-993 (2018)
Obeticholic acid (OCA) is a selective farnesoid X receptor (FXR) agonist that regulates bile acid and lipid metabolism. FXR activation induces distinct changes in circulating cholesterol among animal models and humans. The mechanistic basis of these
Externí odkaz: https://doaj.org/article/5c42e6c6496548ada94d518ab214bf7b
Zobrazit plný text záznamu
2
Validity of biopsy-based drug effects in a diet-induced obese mouse model of biopsy-confirmed NASH
Autor: Michael Feigh, Jacob Jelsing, Sanne Skovgård Veidal, Luciano Adorini, Christina Christoffersen, Jonathan D. Roth, Mary Erickson, Niels Vrang, Maria Kristiansen
Publikováno v: BMC Gastroenterology, Vol 19, Iss 1, Pp 1-11 (2019)
Kristiansen, M N B, Veidal, S S, Christoffersen, C, Feigh, M, Vrang, N, Roth, J D, Erickson, M, Adorini, L & Jelsing, J 2019, ' Validity of biopsy-based drug effects in a diet-induced obese mouse model of biopsy-confirmed NASH ', B M C Gastroenterology, vol. 19, no. 1, 228 . https://doi.org/10.1186/s12876-019-1149-z
BMC Gastroenterology
Background Compounds in clinical development for nonalcoholic steatohepatitis (NASH) improve liver histopathology in diet-induced obese mouse models of biopsy-confirmed NASH. Since the biopsy section used for histopathological evaluation represents o
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::919761ea4372330cd06f0d92d1c6cbb2
https://doaj.org/article/e44142f92aa546f5bc09dfe64650bb25
Zobrazit plný text záznamu
3
Combined obeticholic acid and elafibranor treatment promotes additive liver histological improvements in a diet-induced ob/ob mouse model of biopsy-confirmed NASH
Autor: Mark Young, Jacob Jelsing, Sanne Skovgård Veidal, Niels Vrang, Kristoffer T.G. Rigbolt, Henrik H. Hansen, Jens Nielsen, Louise K. D. Fensholdt, Michael Feigh, Romeo Papazyan, Jonathan D. Roth, Luciano Adorini
Publikováno v: Scientific Reports, Vol 9, Iss 1, Pp 1-13 (2019)
Scientific Reports
Obeticholic acid (OCA) and elafibranor (ELA) are selective and potent agonists for the farnesoid X receptor (FXR) and dual peroxisome proliferator-activated receptor α/δ (PPAR-α/δ), respectively. Both agents have demonstrated clinical efficacy in
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b6c08aeade9907ec908c7907d49c0af9
https://doi.org/10.1038/s41598-019-45178-z
Zobrazit plný text záznamu
4
Amylin/leptin synergy is absent in extreme obesity and not restored by calorie restriction‐induced weight loss in rats
Autor: Peter S. Griffin, Jonathan D. Roth, Jennifer Athanacio, James L. Trevaskis, David G. Parkes, Carrie Wittmer
Publikováno v: Obesity Science & Practice
SummaryObjective Co-administration of amylin and leptin induces synergistic and clinically meaningful (>10%) weight loss that is attenuated as the degree of obesity increases. We explored whether calorie restriction (CR) could restore amylin/leptin s
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9c1c35b447ddb7231ee4eeb2cf6a049b
https://doi.org/10.1002/osp4.62
Zobrazit plný text záznamu
5
INT-767 improves histopathological features in a diet-induced
Autor: Jonathan D, Roth, Michael, Feigh, Sanne S, Veidal, Louise Kd, Fensholdt, Kristoffer T, Rigbolt, Henrik H, Hansen, Li C, Chen, Mathieu, Petitjean, Weslyn, Friley, Niels, Vrang, Jacob, Jelsing, Mark, Young
Publikováno v: World Journal of Gastroenterology
AIM To characterize the efficacy of the dual FXR/TGR5 receptor agonist INT-767 upon histological endpoints in a rodent model of diet-induced and biopsy-confirmed non-alcoholic steatohepatitis (NASH). METHODS The effects of INT-767 on histological fea
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::09efd470ee25c3c9fbdb7ba2a84b8b35
https://pubmed.ncbi.nlm.nih.gov/29375205
Zobrazit plný text záznamu
7
Effects of amylin and bupropion/naltrexone on food intake and body weight are interactive in rodent models
Autor: Pete Griffin, Jason R. Clapper, Jonathan D. Roth, Lawrence J. D'souza, Carrie Wittmer, David G. Parkes, Jennifer Athanacio
Publikováno v: European Journal of Pharmacology. 698:292-298
Antagonism of opioid systems (e.g., with naltrexone) has been explored as an anti-obesity strategy, and is particularly effective when co-administered with dual inhibitors of dopamine and norepinephrine reuptake (e.g., bupropion). Previously, we demo
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0653f76f793bd5b852466d0ca27b929c
https://doi.org/10.1016/j.ejphar.2012.11.010
Zobrazit plný text záznamu
8
Interactive Effects of Neurochemicals on Ingestive Behavior
Autor: Neil E. Rowland, Jonathan D. Roth
Publikováno v: Nutritional neuroscience. 3(3)
Most previous research has focused on the effects of single neurotransmitters and neuropeptides on ingestive behavior. An important next step in the advancement of the science of ingestive behavior is to gain an understanding of how these different s
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3cd2ef34dcc697b7969fc3b13e564d76
https://pubmed.ncbi.nlm.nih.gov/27414050
Zobrazit plný text záznamu
9
Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice
Autor: Brent A. Neuschwander-Tetri, David G. Parkes, Peter S. Griffin, James Napora, Carrie S. Dolman, Elizabeth M. Brunt, Jonathan D. Roth, Mary Erickson, James L. Trevaskis, Carrie Wittmer
Publikováno v: American Journal of Physiology-Gastrointestinal and Liver Physiology. 302:G762-G772
These preclinical studies aimed to 1) increase our understanding the dietary induction of nonalcoholic steatohepatitis (NASH), and, 2) further explore the utility and mechanisms of glucagon-like peptide-1 receptor (GLP-1R) agonism in NASH. We compare
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c63abb343cedd36775c20d42439416ed
https://doi.org/10.1152/ajpgi.00476.2011
Zobrazit plný text záznamu
10
GLP-1R and amylin agonism in metabolic disease: complementary mechanisms and future opportunities
Autor: Jonathan D. Roth, David G. Parkes, Steve Chen, Mary Erickson
Publikováno v: British Journal of Pharmacology. 166:121-136
The discoveries of the incretin hormone glucagon-like peptide-1 (GLP-1) and the β-cell hormone amylin have translated into hormone-based therapies for diabetes. Both classes of molecules also exhibit weight-lowering effects and have been investigate
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8f068a06ea18842c18a6ad78b9f874c6
https://doi.org/10.1111/j.1476-5381.2011.01537.x
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje